Oliver Illini

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Oliver Illini, Maximilian J. Hochmair, Hannah Fabikan et al. · Therapeutic Advances in Medical Oncology · 2021 · 44 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

Maximilian J. Hochmair, Hannah Fabikan, Oliver Illini et al. · Pharmaceuticals · 2020 · 30 citations · Full text

Medicine, Oncology, Pharmacology +15

Real-world experience with capmatinib in <i>MET</i> exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

Oliver Illini, Hannah Fabikan, Aurélie Swalduz et al. · Therapeutic Advances in Medical Oncology · 2022 · 29 citations · Full text

Medicine, Oncology, Pharmacology +17

Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer

Eva Obermayr, Nina Koppensteiner, Nicole Heinzl et al. · Journal of Personalized Medicine · 2021 · 25 citations · Full text

Medicine, Cell Biology, Oncology +17

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy

Felix Carl Saalfeld, Petros Christopoulos, Carina Wenzel et al. · European Journal of Cancer · 2024 · 23 citations · Full text

Medicine, Oncology, Pharmacology +17